Scholar Rock Q4 2025 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy SRRK?
Source: seekingalpha
- Financial Performance: Scholar Rock reported operating expenses of $91.9 million for Q4 2025, including $19.4 million in noncash stock-based compensation, indicating the company's efforts in cost control while laying the groundwork for future product launches.
- Financial Flexibility: The company ended 2025 with $368 million in cash and cash equivalents and secured a new debt facility of up to $550 million with Blue Owl Capital, enhancing financial flexibility to support the upcoming BLA resubmission and market launch.
- Regulatory Progress: Management reiterated guidance for BLA resubmission of apitegromab in 2026, anticipating FDA approval following a successful reinspection, indicating proactive readiness in regulatory compliance that could expedite product launch timelines.
- Supply Chain Redundancy: Progress has been made on engineering runs at a second fill-finish facility, with plans to file a supplemental BLA later this year, demonstrating a forward-looking approach in supply chain management to mitigate potential production risks and ensure market supply.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.310
Low
42.00
Averages
50.00
High
60.00
Current: 44.310
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scholar Rock Q4 2025 Earnings Call Insights
- Financial Performance: Scholar Rock reported operating expenses of $91.9 million for Q4 2025, including $19.4 million in noncash stock-based compensation, indicating the company's efforts in cost control while laying the groundwork for future product launches.
- Financial Flexibility: The company ended 2025 with $368 million in cash and cash equivalents and secured a new debt facility of up to $550 million with Blue Owl Capital, enhancing financial flexibility to support the upcoming BLA resubmission and market launch.
- Regulatory Progress: Management reiterated guidance for BLA resubmission of apitegromab in 2026, anticipating FDA approval following a successful reinspection, indicating proactive readiness in regulatory compliance that could expedite product launch timelines.
- Supply Chain Redundancy: Progress has been made on engineering runs at a second fill-finish facility, with plans to file a supplemental BLA later this year, demonstrating a forward-looking approach in supply chain management to mitigate potential production risks and ensure market supply.
See More
Scholar Rock Revises Q4 and Full Year 2025 Financial Results
- Financial Loss Revision: Scholar Rock reported a net loss of $91 million for Q4 2025, translating to a loss per share of $0.76, compared to $66.5 million and $0.61 in Q4 2024, indicating ongoing financial strain that may impact investor confidence.
- Annual Loss Increase: The total net loss for 2025 reached $377.9 million, significantly up from $246.3 million in 2024, reflecting high R&D and operational expenditures that could challenge future financing capabilities.
- FDA Review Progress: The CEO noted that the FDA's review of apitegromab is progressing well, with plans to resubmit the BLA following successful reinspection, which could open new market opportunities and enhance the company's competitiveness in SMA treatment.
- Future Outlook: Scholar Rock anticipates 2026 to be a transformative year; despite financial challenges, the company is aggressively advancing its pipeline, demonstrating confidence in future growth that may attract long-term investor interest.
See More
Scholar Rock Q4 Earnings Beat Expectations Despite No Revenue
- Earnings Performance: Scholar Rock reported a GAAP EPS of -$0.88 for Q4 2025, beating expectations by $0.01, despite recording no revenue for both Q4 2025 and 2024, indicating ongoing financial challenges.
- Cash Reserves: As of December 31, 2025, Scholar Rock had cash, cash equivalents, and marketable securities totaling $367.6 million, which includes $60.4 million from the exercise of outstanding warrants, providing some financial cushion for future operations.
- Market Response: Despite the lack of revenue, Scholar Rock presented the prospects of its product Apitegromab at the J.P. Morgan Healthcare Conference, maintaining a buy rating, which reflects market confidence in its long-term potential.
- Historical Performance: Historical earnings data for Scholar Rock indicates that the company has faced ongoing revenue challenges over recent quarters, necessitating improvements through product development and market outreach to enhance financial performance.
See More
Scholar Rock to Announce Q4 Earnings on March 2
- Earnings Announcement: Scholar Rock is set to announce its Q4 earnings on March 2 after market close, with consensus EPS estimate at -$0.88 and revenue estimate at $0M, indicating ongoing challenges in profitability.
- EPS Estimate Changes: Over the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting cautious optimism among analysts regarding the company's future performance despite the overall negative outlook.
- Conference Presentation: Scholar Rock presented at the 44th Annual J.P. Morgan Healthcare Conference, which has heightened market interest in its product pipeline, particularly the forward path for Apitegromab.
- Rating Maintenance: Despite challenges, Seeking Alpha maintains a “Buy” rating on Scholar Rock, indicating confidence in its long-term potential, especially with ongoing investments in the biopharmaceutical sector.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation
- Share Acquisition: Redmile Group disclosed a purchase of 1,316,390 shares of Scholar Rock Holding Corporation in an SEC filing dated February 17, 2026, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, highlighting its significance in the fund's asset management and reinforcing its investment strategy in the biopharmaceutical sector.
- Market Performance: As of February 17, 2026, Scholar Rock's shares were priced at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, suggesting positive market expectations regarding its product development.
- Financial Position: Scholar Rock has a market capitalization of $4.78 billion, and while it reported a net income of -$353.43 million, its cash reserves of approximately $365 million provide a buffer for future growth, reducing near-term dilution risk and attracting long-term investors.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation by $49 Million
- Share Acquisition: Redmile Group disclosed in an SEC filing on February 17, 2026, that it purchased 1,316,390 shares of Scholar Rock Holding Corporation, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, representing 16.9% of the fund's 13F reportable assets, further solidifying its investment position in the biopharmaceutical sector.
- Strong Market Performance: As of February 17, 2026, Scholar Rock's share price stood at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, showcasing market recognition of its growth potential.
- Robust Financial Position: Scholar Rock reported approximately $365 million in cash as of December 31, 2026, projected to sustain operations into 2027, thereby reducing near-term dilution risk and providing confidence for long-term investors.
See More
Scholar Rock Q4 2025 Earnings Call Insights
- Financial Performance: Scholar Rock reported operating expenses of $91.9 million for Q4 2025, including $19.4 million in noncash stock-based compensation, indicating the company's efforts in cost control while laying the groundwork for future product launches.
- Financial Flexibility: The company ended 2025 with $368 million in cash and cash equivalents and secured a new debt facility of up to $550 million with Blue Owl Capital, enhancing financial flexibility to support the upcoming BLA resubmission and market launch.
- Regulatory Progress: Management reiterated guidance for BLA resubmission of apitegromab in 2026, anticipating FDA approval following a successful reinspection, indicating proactive readiness in regulatory compliance that could expedite product launch timelines.
- Supply Chain Redundancy: Progress has been made on engineering runs at a second fill-finish facility, with plans to file a supplemental BLA later this year, demonstrating a forward-looking approach in supply chain management to mitigate potential production risks and ensure market supply.
See More
Scholar Rock Revises Q4 and Full Year 2025 Financial Results
- Financial Loss Revision: Scholar Rock reported a net loss of $91 million for Q4 2025, translating to a loss per share of $0.76, compared to $66.5 million and $0.61 in Q4 2024, indicating ongoing financial strain that may impact investor confidence.
- Annual Loss Increase: The total net loss for 2025 reached $377.9 million, significantly up from $246.3 million in 2024, reflecting high R&D and operational expenditures that could challenge future financing capabilities.
- FDA Review Progress: The CEO noted that the FDA's review of apitegromab is progressing well, with plans to resubmit the BLA following successful reinspection, which could open new market opportunities and enhance the company's competitiveness in SMA treatment.
- Future Outlook: Scholar Rock anticipates 2026 to be a transformative year; despite financial challenges, the company is aggressively advancing its pipeline, demonstrating confidence in future growth that may attract long-term investor interest.
See More
Scholar Rock Q4 Earnings Beat Expectations Despite No Revenue
- Earnings Performance: Scholar Rock reported a GAAP EPS of -$0.88 for Q4 2025, beating expectations by $0.01, despite recording no revenue for both Q4 2025 and 2024, indicating ongoing financial challenges.
- Cash Reserves: As of December 31, 2025, Scholar Rock had cash, cash equivalents, and marketable securities totaling $367.6 million, which includes $60.4 million from the exercise of outstanding warrants, providing some financial cushion for future operations.
- Market Response: Despite the lack of revenue, Scholar Rock presented the prospects of its product Apitegromab at the J.P. Morgan Healthcare Conference, maintaining a buy rating, which reflects market confidence in its long-term potential.
- Historical Performance: Historical earnings data for Scholar Rock indicates that the company has faced ongoing revenue challenges over recent quarters, necessitating improvements through product development and market outreach to enhance financial performance.
See More
Scholar Rock to Announce Q4 Earnings on March 2
- Earnings Announcement: Scholar Rock is set to announce its Q4 earnings on March 2 after market close, with consensus EPS estimate at -$0.88 and revenue estimate at $0M, indicating ongoing challenges in profitability.
- EPS Estimate Changes: Over the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting cautious optimism among analysts regarding the company's future performance despite the overall negative outlook.
- Conference Presentation: Scholar Rock presented at the 44th Annual J.P. Morgan Healthcare Conference, which has heightened market interest in its product pipeline, particularly the forward path for Apitegromab.
- Rating Maintenance: Despite challenges, Seeking Alpha maintains a “Buy” rating on Scholar Rock, indicating confidence in its long-term potential, especially with ongoing investments in the biopharmaceutical sector.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation
- Share Acquisition: Redmile Group disclosed a purchase of 1,316,390 shares of Scholar Rock Holding Corporation in an SEC filing dated February 17, 2026, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, highlighting its significance in the fund's asset management and reinforcing its investment strategy in the biopharmaceutical sector.
- Market Performance: As of February 17, 2026, Scholar Rock's shares were priced at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, suggesting positive market expectations regarding its product development.
- Financial Position: Scholar Rock has a market capitalization of $4.78 billion, and while it reported a net income of -$353.43 million, its cash reserves of approximately $365 million provide a buffer for future growth, reducing near-term dilution risk and attracting long-term investors.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation by $49 Million
- Share Acquisition: Redmile Group disclosed in an SEC filing on February 17, 2026, that it purchased 1,316,390 shares of Scholar Rock Holding Corporation, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, representing 16.9% of the fund's 13F reportable assets, further solidifying its investment position in the biopharmaceutical sector.
- Strong Market Performance: As of February 17, 2026, Scholar Rock's share price stood at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, showcasing market recognition of its growth potential.
- Robust Financial Position: Scholar Rock reported approximately $365 million in cash as of December 31, 2026, projected to sustain operations into 2027, thereby reducing near-term dilution risk and providing confidence for long-term investors.
See More
